BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ —
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results
from a Phase Ib study, SOUND-C1, that showed the combination of two
oral hepatitis C virus (HCV) compounds, the protease inhibitor BI
201335 and the polymerase inhibitor BI 207127, with ribavirin
reduced viral load below the lower limit of quantifiable levels in
HCV treatment-naive patients. The regimen did not include
interferon through the first 28 days of treatment. These data are
being presented at the American Association for the Study of Liver
Diseases (AASLD) 2010 Liver Meeting in Boston, MA.
(Poster LB-7) New protease-polymerase inhibitor combination
resulted in 73-100% rapid virological responses without pegylated
interferonIn this randomized open-label trial, 32 treatment-naive
genotype-1 HCV patients received BI 207127 in either 400mg or 600mg
doses three times a day (TID), BI 201335 120mg once daily (QD) and
ribavirin (RBV) (1000/1200mg daily in two doses) for 28 days. All
patients had a rapid and sharp decline in HCV viral load during the
first two days, followed by a slower second phase decline. In the
lower and higher dose groups, 73 and 100% of patients achieved a
rapid virological response (i.e. HCV RNA below lower limit of
quantification after 4 weeks of treatment). One patient experienced
a viral breakthrough (increase by >1 LOG10 from nadir during
treatment) and one other experienced a 0.7 LOG10 increase in viral
load. Both were in the lower dose group of BI 207127 and were
patients with high baseline viral load. On day 29, all patients
were switched to treatment with BI 201335 and PegIFN/RBV for an
additional 44 weeks per the defined study protocol, and will be
followed to evaluate sustained virological response.
“The current standard-of-care, PegIFN/RBV, is challenging for
patients with chronic hepatitis C due to significant side effects
that impact treatment adherence and has suboptimal response
‘/>”/>
